PRL and type 2 diabetes mellitus: They suggest that metformin, at least when it is administered as a monotherapy, does not seem to be the drug of choice in the treatment of macroprolactinemic patients with type 2 diabetes and in the prevention of this disorder in high-risk patients with increased levels of high-molecular-weight prolactin.